HR heads into today's Q2 earnings with short sellers backing away and options traders turning notably more cautious, creating a split signal into the release.
The clearest shift in positioning is on the short side — and it points to retreat, not aggression. Short interest has fallen nearly 7.5% over the past week to roughly 4.9% of the free float, continuing a drawdown from a mid-July peak near 5.7% of float. That move lower is reinforced by a deeply relaxed borrow market: availability runs at around 916% — meaning for every share currently borrowed, more than nine sit unused in the lending pool. Cost to borrow has also eased, dropping more than 20% over the month to just 0.39%. For a stock up 4% over the past month and 28% year-to-date, the shorts are not pressing their case.
Options tell a different story. Defensive positioning has jumped to its most elevated level in several weeks. The put/call ratio hit 0.16 on Wednesday — nearly 2.4 standard deviations above its 20-day average of 0.09. That's a sharp and sudden spike from a prolonged flat stretch in the 0.087–0.088 range that lasted most of July, suggesting traders bought downside protection specifically in the two sessions immediately before the print. HR fell 1.3% on Wednesday, its first meaningful one-day decline in recent weeks, to close at $21.53.
The analyst community has converged on a cautious consensus. The headline rating is a hold, with nine holds recorded and no buys from the most recent update. JP Morgan and UBS both lifted their price targets to $21 in early July — essentially matching the current price, implying the Street sees no near-term upside from here. Raymond James is the outlier: it reinstated coverage in mid-June with an Outperform and a $24 target, arguing the REIT's 36 million square feet of medical office portfolio and higher-than-expected rent growth justify a premium. Bears counter that NAV has been declining, occupancy remains under pressure, and the 28% year-to-date rally has already compressed any valuation buffer. The EV/EBITDA multiple has drifted lower over the past month, and EPS momentum ranks near the bottom of the universe at the 2nd percentile on a 30-day basis — a sign that estimate cuts have been running ahead of the price.
Institutional ownership offers one supporting note: BlackRock added over 1.2 million shares in the most recent quarter to hold nearly 16% of the company, and T. Rowe Price added another million shares. With the stock's one prior earnings reaction on record showing a 4.7% one-day gain and 7.8% five-day gain following the May print, today's release tests whether HR can demonstrate the occupancy recovery and rent growth needed to justify a valuation that has now outrun the majority of analyst targets.
See the live data behind this article on ORTEX.
Open HR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
